Related Experiment Video
Updated: Feb 13, 2026

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
Integrative Machine Learning and Experimental Validation Identify FIS1 as a Candidate Biomarker Linked to
Yu Zhang1,2, Qing Dai2,3, Lijun Gong2,3
1School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
This study reveals that increased FIS1 expression drives pulmonary hypertension (PH) by causing mitochondrial fragmentation and ferroptosis in pulmonary artery smooth muscle cells, contributing to vascular remodeling.
Area of Science:
- Mitochondrial biology
- Cardiovascular research
- Molecular pathology
Background:
- Pulmonary hypertension (PH) involves complex pulmonary vascular remodeling with limited treatments.
- Mitochondrial dynamics are implicated in PH pathogenesis, but key regulators are undefined.
Purpose of the Study:
- To identify and functionally characterize genes regulating mitochondrial dynamics in PH.
- To explore the role of identified genes in pulmonary artery smooth muscle cell (PASMC) dysfunction and PH.
Main Methods:
- Integrated transcriptomic data with mitochondrial annotations.
- Prioritized candidate genes using WGCNA and machine learning.
- Validated findings in hypoxia-induced PH mouse models and cultured mouse PASMCs (mPASMCs) using molecular and cellular assays.
Main Results:
- Identified FIS1 as a key gene associated with PH, showing high discriminatory performance.
- Hypoxia increased FIS1 expression, leading to mitochondrial fragmentation, membrane potential loss, and ROS accumulation in mPASMCs.
- FIS1 knockdown suppressed mPASMC proliferation and migration, reduced mitochondrial injury, and attenuated ferroptosis.
Conclusions:
- FIS1 contributes to PH pathogenesis via mitochondrial fission and ferroptosis, promoting aberrant PASMC phenotypes and vascular remodeling.
- This study offers mechanistic insights and potential therapeutic targets within mitochondrial pathways for PH.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Reliability and Validity

